Pfizer Research Grant Request for Proposals: Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways supports basic science research aimed at elucidating the molecular and cellular mechanisms underlying marstacimab–TFPI interactions. This competitive grant program, governed by Pfizer’s internal review process, invites proposals that advance foundational understanding of Tissue Factor Pathway Inhibitor (TFPI) biology, anti-TFPI monoclonal antibodies, and marstacimab through innovative approaches in biochemistry, molecular biology, and related disciplines.

Overview

This grant program encompasses research into the biochemical and molecular characterization of marstacimab and TFPI pathways. Projects should seek to clarify the mechanisms of marstacimab–TFPI interactions, including but not limited to differential expression of tissue factor and TFPI in various tissues, binding kinetics, and other biochemical properties. The program prioritises fundamental biological understanding of TFPI, anti-TFPI monoclonal antibodies, and marstacimab within the context of haemophilia and other bleeding disorders.

Research Areas

Proposals may address, but are not limited to, the following areas of interest:

• Basic biology of TFPI, including interactions among key regulatory proteins in the intrinsic and/or extrinsic clotting cascades (e.g., Protein S as a co-factor for both Protein C and TFPI).
• Impact of differential TFPI expression within tissues and the role of various TFPI pools and isoforms in the regulation of coagulation.
• Pharmacology resulting from concomitant therapies added to anti-TFPI agents.

Funding and Benefits

• Individual project request limit: Up to $50,000 USD.
• Study drug support: Requests for study drug or compound are allowed up to a maximum of $50,000 USD, in addition to project costs.
• Combined maximum: Total project costs and study drug costs must not exceed $100,000 USD.
• Total available budget: Approximately $300,000 USD across all awards.
• Overhead: Institutional overhead capped at 28% per Pfizer policy.
• Project length: Maximum of one year.

Eligibility

Geographic scope: Brazil, China, Germany, Italy, Japan, Netherlands, Saudi Arabia, South Korea, Spain, Turkey, United Kingdom, and United States.

Applicant and institutional criteria:

• The institution and Principal Investigator (PI) must be based in one of the eligible countries.
• Only organisations are eligible to receive grants. Individuals and independent medical practice groups not affiliated with a hospital, academic institution, or professional society are not eligible.
• For multi-department or multi-institution projects, all institutions must have a relevant role, and the requesting organisation must hold a key role.
• The PI must hold a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with an MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
• The applicant must be the PI or an authorised designee (e.g., the PI’s research coordinator).
• The PI must be an employee or contractor of the requesting organisation.
• The requesting organisation must be legally able to receive award funding directly from Pfizer Inc.

Application Process

Applications must be submitted through the online portal at www.cybergrants.com/pfizer/Research. First-time users should click “Create your password” and then “Start A New Research Grant Application”.

Submission requirements:

• Complete all required sections of the online application.
• Upload the full proposal in the Proposal/Protocol field.
• For the question “Competitive Grant?” select “Yes”.
• Select the Primary Area of Interest: Bleeding Disorders – RES.
• Select the Competitive Grant Program Name: 2026 RD G Rare Bleeding TFPI Pathways RES.

Proposals should be single-spaced, Calibri 12-point font, with 1-inch margins, and must not exceed 15 pages (exclusive of references). The full proposal must address: goals and objectives, assessment of need, target audience, project design and methods, innovation, evaluation and outcomes, anticipated project timeline, additional information, organisation details, and a detailed budget in USD.

Deadline and Timeline

• RFP release date: 13 May 2026
• Submission deadline: 1 July 2026, 23:59 Eastern Standard Time (New York, GMT–5). Applications submitted after the deadline will not be reviewed.
• Anticipated grant award notification: 8 October 2026
• Anticipated project start date: 1 January 2027
• Anticipated project end date: 31 December 2027

Applicants will be notified via email. Organisations must obtain IRB approval prior to 1 December 2026 to remain eligible for award funding.

For questions regarding this RFP, direct written inquiries to the Grant Officer, Talita Honorato-Rzeszewicz, at Talita.honorato-rzeszewicz@pfizer.com with the subject line “2026 RD G Rare Bleeding TFPI Pathways RES”.